Research Sponsored by
Despite major advances in the pharmaceutical treatment of disease, many children reject medicines due to an aversion to bitter taste.
A new review called "Relationship Between Bitter-Taste Receptor Genotype and Solid Medication Formulation Usage Among Young Children: A Retrospective Analysis," published online ahead of print in Clinical Therapeutics, addresses this critical problem by highlighting recent advances in the scientific understanding of bitter taste, with special attention to the sensory world of children.
Written by an interdisciplinary team of taste scientists from the Monell Chemical Senses Center, Florida State University, and the University of Washington, the paper focuses on applying this knowledge to improve drug acceptance and compliance in pediatric populations. It says several biological factors highlight the importance of understanding bitter taste to the successful formulation of pediatric medications. Bitter taste is thought to have evolved as a protection against toxins, as many poisons taste bitter. Because of this, it is very difficult to disguise or mask bitterness. Compounding this problem is the fact that children, who are especially sensitive to bitterness, cannot swallow pills or tablets, which encapsulate bitterness in adult formulations.
The review summarizes current knowledge on how bitter taste works from a biological perspective and provides a comprehensive overview of methods used to assess taste responses in children. The authors point out critical gaps in the existing understanding of how best to measure bitterness in children, whose cognitive and perceptual abilities differ from those of adults.
“The problems associated with pediatric drug formulations are enormous and can hinder optimal therapeutic outcomes,” said lead author Julie Mennella, a developmental psychobiologist at Monell. “Both the complexity of bitter taste and the unique sensory world of children contribute to this critical issue.”